Matthew Hamilton Rosenberg’s Regeneron Pharmaceuticals REGN Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.4K	Hold	60	–	–	0.01%	471
2026 Q1	$46.4K	Hold	60	–	–	0.01%	430
2025 Q4	$46.3K	Hold	60	–	–	0.01%	437
2025 Q3	$33.7K	Hold	60	–	–	0.01%	472
2025 Q2	$31.5K	Hold	60	–	–	0.01%	503
2025 Q1	$38.1K	Hold	60	–	–	0.01%	465
2024 Q4	$42.7K	Sell	60 -6	-9%	-$5.04K	0.01%	442
2024 Q3	$69.4K	Hold	66	–	–	0.02%	377
2024 Q2	$69.8K	Hold	66	–	–	0.02%	366
2024 Q1	$64K	Hold	66	–	–	0.02%	388
2023 Q4	$58K	Buy	66 +6	+10%	+$4.94K	0.02%	405
2023 Q3	$49.4K	Hold	60	–	–	0.02%	423
2023 Q2	$43.1K	Hold	60	–	–	0.01%	456
2023 Q1	$49.3K	Hold	60	–	–	0.02%	467
2022 Q4	$43.3K	Hold	60	–	–	0.01%	495
2022 Q3	$41K	Hold	60	–	–	0.02%	487
2022 Q2	$36K	Hold	60	–	–	0.01%	521
2022 Q1	$42K	Hold	60	–	–	0.01%	481
2021 Q4	$38K	Buy	+60	New	+$36.9K	0.01%	457

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Matthew Hamilton Rosenberg's REGN Position: Q2 2026 in Review

Matthew Hamilton Rosenberg held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 60 shares worth $37.4K. The position accounts for 0.01% of the portfolio, ranked #471.

Matthew Hamilton Rosenberg first reported a position in REGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $69.8K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Matthew Hamilton Rosenberg held 60 shares of Regeneron Pharmaceuticals worth $37.4K as of Q2 2026.
Matthew Hamilton Rosenberg left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Matthew Hamilton Rosenberg's portfolio in Q2 2026, its #471 holding.
Matthew Hamilton Rosenberg first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Matthew Hamilton Rosenberg's Regeneron Pharmaceuticals position peaked at $69.8K in Q2 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Matthew Hamilton Rosenberg's 13F filing for Q2 2026, filed 17 Jul 2026.